Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Fernández Villegas, Ana ^a   Pinazo, María J ^b   Marañón, Concepción ^a   Thomas, M Carmen ^a   Posada, Elizabeth ^b   Carrilero, Bartolomé ^c   Segovia, Manuel ^c   Gascon, Joaquim ^b   López, Manuel C ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; EPITOPE; HEAT SHOCK PROTEIN 70; KMP11 ANTIGEN; PFR2 ANTIGEN; RECOMBINANT PROTEIN; TGP63 ANTIGEN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM DISEASE; DISEASE CLASSIFICATION; DYNAMICS; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; IMMUNOREACTIVITY; LEPROSY; MALARIA; MALE; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; TRYPANOSOMA CRUZI; TUBERCULOSIS; VIRUS TRANSMISSION; ADOLESCENT; AGED; BLOOD; DRUG MONITORING; EVALUATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; BIOLOGICAL MARKERS; CHAGAS DISEASE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960870288     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-206     Document Type: Article

References (38)

1. Guhl F, Lazdins-Helds JK. The Special Programme for Research and Training in Tropical Diseases (TDR). 2007, 97.
2. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol 2006, 22:583-588. 10.1016/j.pt.2006.09.011, 17049308.
3. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010, 375:1388-1402. 10.1016/S0140-6736(10)60061-X, 20399979.
4. Munoz J, Gomez I, Prat J, Gallego M, Gimeno F, Trevino B, López-Chejade P, Ribera O, Molina L, Sanz S, Pinazo MJ, Riera C, Posada EJ, Sanz G, Portús M, Gascon J. Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop 2009, 111:51-55. 10.1016/j.actatropica.2009.02.005, 19426663.
5. Jackson Y, Myers C, Diana A, Marti HP, Wolff H, Chappuis F, Loutan L, Gervaix A. Congenital transmission of Chagas disease in Latin American immigrants in Switzerland. Emerg Infect Dis 2009, 15:601-603. 10.3201/eid1504.080438, 2671437, 19331743.
6. Munoz J, Coll O, Juncosa T, Vergés M, del Pino M, Fumado V, Bosch J, Posada EJ, Hernandez S, Fisa R, Boguña JM, Gállego M, Sanz S, Portús M, Gascón J. Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clinc Infect Dis 2009, 248:1736-1740.
7. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001, 1:92-100. 10.1016/S1473-3099(01)00065-2, 11871482.
8. Dutra WO, Rocha MO, Teixeira MM. The clinical immunology of human Chagas disease. Trends Parasitol 2005, 21:581-587. 10.1016/j.pt.2005.09.007, 16236550.
9. Rassi A, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol 2000, 23:883-889. 10.1002/clc.4960231205, 11129673.
10. Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC. Clinical aspects of the Chagas' heart disease. Int J Cardiol 2007, 115:279-283. 10.1016/j.ijcard.2006.03.004, 16769134.
11. Pinazo MJ, Cañas E, Elizalde JI, García M, Gascón J, Gimeno F, Gomez J, Guhl F, Ortiz V, Posada Ede J, Puente S, Rezende J, Salas J, Saravia J, Torrico F, Torrus D, Treviño B. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010, (33):191-200.
12. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006, 144:724-734.
13. Marin-Neto JA, Rassi A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the Benznidazole Evaluation For Interrupting Trypanosomiasis. Am Heart J 2008, 156:37-43. 10.1016/j.ahj.2008.04.001, 18585495.
14. Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop 2010, 115(1-2):55-68. 10.1016/j.actatropica.2009.10.023, 19900395.
15. Berrizbeitia M, Ndao M, Bubis J, Gottschalk M, Aché A, Lacouture S, Medina M, Ward BJ. Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains. Transfus Med 2006, 16:419-431. 10.1111/j.1365-3148.2006.00703.x, 17163873.
16. Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin Vaccine Immunol 2007, 14:1045-1049. 10.1128/CVI.00127-07, 2044488, 17522327.
17. Otani MM, Vinelli E, Kirchhoff LV, del Pozo A, Sands A, Vercauteren G, Sabino EC. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 2009, 49:1076-1082. 10.1111/j.1537-2995.2009.02107.x, 19290995.
18. WHO Control of Chagas disease. World Health Organ Tech Rep Ser 2002, 905:i-vi. 1-109, back cover, WHO.
19. Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002, 44:29-37. 10.1590/S0036-46652002000100006, 11896410.
20. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macêdo V, Fernandes O. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 2001, 96:823-826. 10.1590/S0074-02762001000600014, 11562709.
21. Solari A, Ortíz S, Soto A, Arancibia C, Campillay R, Contreras M, Salinas P, Rojas A, Schenone H. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J Antimicrob Chemother 2000, 48:515-519.
22. Sánchez Negrette O, Sánchez Valdéz FJ, Lacunza CD, García Bustos MF, Mora MC, Uncos AD, Basombrío MA. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clin Vaccine Immunol 2008, 15:297-302. 10.1128/CVI.00106-07, 2238061, 18057184.
23. Cooley G, Etheridge RD, Boehlke C, Bundy B, Weatherly DB, Minning T, Haney M, Postan M, Laucella S, Tarleton RL. High Throughput Selection of Effective Serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis 2008, 2(10):e316. 10.1371/journal.pntd.0000316, 2556098, 18841200.
24. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985, 45:249-256.
25. Bouvier J, Etges RJ, Bordier C. Identification and purification of membrane and soluble forms of the major surface protein of Leishmania promastigotes. J Biol Chem 1985, 260:15504-15509.
26. Puentes F, Guzmán F, Marín V, Alonso C, Patarroyo ME, Moreno A. Leishmania: fine mapping of the Leishmanolysin molecule's conserved core domains involved in binding and internalization. Exp Parasitol 1999, 93:7-22. 10.1006/expr.1999.4427, 10464034.
27. Thomas MC, Garcia-Perez JL, Alonso C, Lopez MC. Molecular characterization of KMP11 from Trypanosoma cruzi: a cytoskeleton-associated protein regulated at the translational level. DNA Cell Biol 2000, 19:47-57. 10.1089/104454900314708, 10668791.
28. Maranon C, Planelles L, Alonso C, Lopez MC. HSP70 from Trypanosoma cruzi is endowed with specific cell proliferation potential leading to apoptosis. Int Immunol 2000, 12:1685-1693. 10.1093/intimm/12.12.1685, 11099308.
29. Morell M, Thomas MC, Caballero T, Alonso C, Lopez MC. The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine 2006, 24:7046-7055. 10.1016/j.vaccine.2006.07.006, 16901590.
30. Thomas MC, Longobardo MV, Carmelo E, Marañón C, Planelles L, Patarroyo ME, Alonso C, López MC. Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera. Clin Exp Immunol 2001, 123:465-471. 10.1046/j.1365-2249.2001.01478.x, 1906009, 11298135.
31. Requena JM, Soto M, Guzman F, Maekelt A, Noya O, Patarroyo ME, Alonso C. Mapping of antigenic determinants of the T. cruzi hsp70 in chagasic and healthy individuals. Mol Immunol 1993, 30:1115-1121. 10.1016/0161-5890(93)90158-8, 8366861.
32. Shreffler WG, Burns JM, Badaró R, Ghalib HW, Button LL, McMaster WR, Reed SG. Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J Infect Dis 1993, 167:426-430. 10.1093/infdis/167.2.426, 7678428.
33. Flechas ID, Cuellar A, Cucunubá ZM, Rosas F, Velasco V, Steindel M, Thomas MC, López MC, González JM, Puerta C. Characterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients. BMC Infect Dis 2009, 9:186. 10.1186/1471-2334-9-186, 2789076, 19939275.
34. Rocha GM, Teixeira DE, Miranda K, Weissmüller G, Bisch PM, de Souza W. Structural changes of the paraflagellar rod during flagellar beating in Trypanosoma cruzi. PLoS One 2010, 5:e11407. 10.1371/journal.pone.0011407, 2894934, 20613980.
35. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994, 127:151-162. 10.1016/0002-8703(94)90521-5, 8273735.
36. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Armenti A, Tarleton RL. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009, 49:1675-1684. 10.1086/648072, 2805187, 19877967.
37. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005, 49:1521-1528. 10.1128/AAC.49.4.1521-1528.2005, 1068607, 15793134.
38. Fernandez MC, Gonzalez Cappa SM, Solana ME. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection. Exp Parasitol 2010, 124:172-180. 10.1016/j.exppara.2009.09.006, 19747482.